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Summary EL4 tumour cells maintained in culture were separated by FACS analysis to Ly-6.2 negative and
Ly-6.2 positive subsets. The Ly-6.2 negative subset gained expression of this determinant on repeated in vivo
passage in C57BL/6 mice. Both subsets injected intraperitoneally or intramuscularly in syngeneic mice induced
identical changes in lymphocyte profiles. There was generalised lymphocytolysis in both T- and B-cell
compartments. The Lyt-l +, 2- T-lymphocytes were more susceptible to cytolysis causing an alteration of the
proportional representation of the Lyt-2+ subset from 30% of splenic T-cells (in normal mice) to over 90% of
remaining T-lymphocytes in tumour bearing mice. There was thymic regression in both groups of mice with a
resultant thymocyte population expressing the range ofphenotypes of mature medullary cells.
In spite of similar rates of growth both in vivo and in vitro and identical effects on the lymphoid system the
Ly-6.2 negative and Ly-6.2 positive tumour subsets were different in their metastatic potential. Mice injected
intramuscularly with either subset had enlarged spleens by the second week of tumour growth caused largely
by the accumulation of Ig, Lyt-l and Thy-i negative cells. Tumour cells were present only in the group
injected with the Ly-6.2+ subset. These mice died of their tumour load a week earlier than those injected with
the Ly-6.2- tumour cells.
Tumour cell populations are heterogeneous with respect to a
variety of properties that influence their growth and survival
in the host (Poste & Fidler, 1980; Nicholson, 1984).
Development of heterogeneity is thought to be part of the
tumorigenic process causing the progression of primary
tumours from the benign to the malignant state (Harris et
al., 1982; Fidler & Hart, 1982). This may involve the
selection of stable subpopulations of cells in the original
tumour which possess intrinsic properties that promote dis-
semination; it may also reflect the acquisition of such
properties due to genetic alterations that may arise under the
influence of selective pressures of the host response (Layton
& Franks, 1984; Bernstein & Weinberg, 1985).
Comparative examinations of metastatic variants and
parental tumour lines have centred on the study of cell
surface compositions of neoplastic cell lines. Quantitative
differences in terminal cell surface carbohydrates (Fogl et al.,
1983), altered cell surface protein composition after enzyme
treatment (Sargent et al., 1983) and differences in glyco-
protein expression (Altevogt et al., 1982) have all been
shown to contribute to the metastatic capacity of different
tumour cell lines. The most notable finding to date is an
inverse correlation between metastatic potential and the
expression of major histocompatibility complex (MHC)
molecules (Wallich et al., 1985; Hui et al., 1984; Albino et
al., 1981; Natali et al., 1983).
In this study we demonstrate that in the EL4 murine T-
cell leukaemia model there is a direct relationship between
expression of the lymphocyte differentiation antigen Ly-6.2
and dissemination of the tumour cells to the spleen and
lymph nodes from an intramuscular site. EL4 tumour cells
maintained in culture are heterogeneous with respect to Ly-
6.2 expression. Tumour cells selected by fluorescence
activated cell sorter (FACS) analysis on the basis of lack of
expression of Ly-6.2, gained this determinant on in vivo
passage while parallel in vitro cultures remained negative. To
determine the biological effects of Ly-6.2 expression on EL4
tumour cells, Ly-6.2- and Ly-6.2+ tumour cells were injected
into syngeneic C57BL/6 mice and their effects on lymphocyte
profiles and capacity to metastasize into the lymphoid
organs examined.
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Materials and methods
Mice
Six to eight week old C57BL/6 mice bred in our animal
facilities were used.
Culture of tumour cells
EL4 tumour cells were maintained in culture by twice weekly
passage in RPMI 1640 containing 10% foetal calf serum
(FCS) and antibiotics. The cell line was tested and shown to
be free ofmycoplasma.
Reagentsforfluorescence staining
Monoclonal anti-Ly-6.2 (S8.106) which recognises the
classical Ly-6.2 antigen (Kimura et al., 1984) was kindly
provided by Dr U. Hammerling of the Sloan Kettering
Cancer Institute. It was used in conjunction with a
fluorescein-conjugated monoclonal anti-Igh-Ia (21-74.4) (Oi
& Herzenberg, 1979) as a second step reagent. Monoclonal
antibodies against Thy-I and Lyt-2 were derived from
hybridoma clones 53-2.1 and 53-6.7 respectively (Ledbetter &
Herzenberg, 1979). They were used as direct fluorescein
conjugates.
Fluorescence staining ofcell suspensions
This was carried out as previously described (Mattosian-
Rogers et al., 1982). Briefly cells were suspended in RPMI
containing 1% foetal calf serum and 0.1% NaN3 and
incubated for 30min on ice with saturating levels of the
monoclonal reagents. Cell suspensions reacting with anti-Ly-
6.2 were washed and incubated for a further 30min with
fluorescein-conjugated anti-allotype monoclonal reagent anti-
Igh-la (IgG-2a), the second step reagent. Fluorescence
profiles were obtained using a modified FACS II (Becton-
Dickinson FACS Systems, Mountain View, California).
Separation ofEL4 tumour cells to Ly-6.2- and Ly-6.2+
subpopulations
Tumour cells were stained with anti-Ly-6.2 under sterile
conditions as described above. The staining profile was
examined by fluoroscence activated cell sorter (FACS)
analysis and the criteria for sorting the dullest and the
brightest cells were established. The sorted populations were
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washed and incubated in culture medium at 1 x 10 mlP1.
They were counted at 3 day intervals and reseeded at
1 x IO1 ml-1 in fresh culture medium.
Experimental design
Groups of age matched female C57BL/6 mice were injected
with 5 x 105 Ly-6.2- or Ly-6.2+ EL4 tumour cells either
intraperitoneally (i.p.) or intramuscularly (i.m.) in one hind
leg. Some groups were observed for duration of survival
while others were examined for tumour metastasis and
alterations in lymphocyte profiles. At weekly intervals the
thymus, lymph nodes and spleen were removed and cell
suspensions from these organs were stained with monoclonal
reagents and analysed by fluorimetry. Tumour cells were
also removed from the peritoneal cavity or the solid
intramuscular growth and the staining characteristics
examined.
Results
Gain ofLy-6.2 expression ofEL4 tumour cells passaged in
ascites
EL4 tumour cells maintained by serial passage in culture
medium were heterogeneous with respect to Ly-6.2
expression. FACS analysis of the Ly-6.2 staining profile of
such tumour cells is shown in Figure 1. When the cultured
tumour cells were injected into C57BL/6 mice either i.p. or
i.m. there was an increase in expression of Ly-6.2 so that
tumour cells obtained from the second passage were over
90% Ly-6.2 positive. Ly-6.2 staining profiles of first and
second passage tumour cells are shown in Figure la. Thy-1.2
staining of the in vitro cultured and the in vivo passaged
tumour cells did not vary significantly (Figure lb). Transfer
of in vivo passaged tumour cells to in vitro culture conditions
resulted in the gradual loss of Ly-6.2 expression and reversal
to the heterogeneous profile shown in Figure la.
Fluorescence-activated cell sorting ofEL4 cells to Ly-6.2-
and Ly-6.2+ subpopulations
In vitro maintained EL4 tumour cells were stained with anti-
Ly-6.2 under sterile conditions and sorted to Ly-6.2- and
Ly-6.2+ subpopulations. The fluorescence intensity of the
unsorted population on the arbitrary log10 scale of 0-4
ranged from 0.8 to 3.5. The fluorescence intensity of the Ly-
6.2- population ranged from 0.8 to 1.8 and the Ly-6.2+
population from 1.8 to 3.5. To eliminate the possibility of
contamination sorting criteria were set to select cells with a
fluorescence intensity of 0.8 to 1.2 and 2.0 to 3.5 for the Ly-
6.2- and Ly-6.2+ populations respectively. Ly-6.2- cells
above 1.2 log units and Ly-6.2+ cells of intermediate
brightness which fell in the intervening 0.8 log1o units were
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discarded. The fluorescence patterns of the sorted
populations revealed absolute purity of separation (Figure
2). The two populations were maintained as separate lines in
culture and their rate of growth and staining characteristics
examined for a number of passages. The Ly-6.2 negative line
maintained this phenotype for at least 18 passages during a
period of 9 weeks. During this time the Ly-6.2 positive line
showed a gradual loss of Ly-6.2 expression. The rate of
growth of the two sublines was identical during the 9 week
observation period.
Effects ofLy-6.2- and Ly-6.2+ EL4 tumour cells injected
intraperitoneally into syngeneic mice
The separated Ly-6.2 negative and Ly-6.2 positive EL4
tumour cells were injected i.p. into groups of five C57BL/6
female mice. At weekly intervals the staining patterns of the
tumour cells recovered from the mice and the lymphocytes
obtained from the thymus spleen and lymph nodes were
examined.
At the end of the first week there were no noticeable
changes in the sizes of the lymphoid organs; lymphocyte
profiles were also unchanged compared to normal mice. At
the end of the second week the spleens of the mice that had
received the Ly-6.2+ tumour cells were enlarged while the
spleens of mice injected with Ly-6.2- tumour cells appeared
normal (Table I). Flow-cytometric analysis revealed similar
deviations from normal lymphocyte profiles for both groups
of mice. There was a reduction in number of splenic Thy-I +
cells from 30-35% in normal mice to 10-15% in the tumour
bearing mice. Over 90% of these Thy-i+ cells were Lyt-2+
whereas in the normal mouse Lyt-2+ cells comprise 30% of
splenic T-cells (Figure 3). Similar changes in lymphocyte
profile were noted in the lymph nodes of both groups of
mice.
The thymuses of all mice from both groups showed
marked regression. The thymocytes that were recovered were
phenotypically identical to mature medullary thymocytes.
Lyt-2 staining cells were reduced from 70-80% in the normal
thymus to 28-30% in both groups of mice. There was a
marked decrease in brightness of Thy-I
' cells and an
enrichment of Ly-6.2+ thymocytes from undectable levels in
normal C57BL/6 mice to 50-60% in the tumour bearing
mice (Figure 4). Tumour cells recovered from the peritoneal
cavity of mice from the two groups did not show identical
staining profiles. Mice that were injected with the Ly-6.2-
subline yielded a tumour cell population that was 50-60%
Ly-6.2+ while tumour cells recovered from the mice that
received the Ly-6.2+ EL4 cells were almost totally Ly-6.2
positive (Figure 5).
Metastatic potential ofLy-6.2- and Ly-6.2+ tumour cells
injected intramuscularly into syngeneic hosts
When Ly-6.2- and Ly-6.2+ tumour cells were injected i.m.
similar changes to those described above occurred in the
lymphocyte and thymocyte populations during the second
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Figure 1 FACS analysis of (a) Ly-6.2 and (b) Thy-1.2 staining
profiles of EL4 tumour cells cultured in vitro (. ) and
after one ( ----- ) and two ( ) passages (i.p.) in C57BL/6
mice. The fine line on (a) and (b) ( ) represents the
fluorescence of tumour cells stained with second step reagent
alone.
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Figure 2 Ly-6.2 staining profiles of the Ly-6.2 negative ( )
and Ly-6.2 brightly staining (----- ) EL4 tumour cells after
sorting by the FACS.740 A. MATOSSIAN-ROGERS & P.D. ROGERS
Table I Spleen weights of C57BL/6 mice injected i.p. or i.m. with
5 x 105 Ly-6.2- or Ly-6.2+ EL4 tumour cells
Spleen weights (mg±s.d.) 7 and 14 days after
injection with tumour cells
7 days 14 days
Route of
tumour injection Ly-6.2- Ly-6.2+ Ly-6.2- Ly-6.2+
i.p. 77+12 90+10 81+ 5 166+ 35
NSa p<0.001
i.m. 85+15 93+16 453+87 546+102
NS NS
Spleen weights of uninjected C57BL/6 mice were 80+8mg which
is not significantly different from the spleens of mice injected 7 days
previously by either route. Statistical analyses were carried out using
Student's t-test.
'NS - not significantly different.
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Figure 3 FACS analysis of splenocytes from normal (
and tumour-bearing (.- ) C57BL/6 mice stained with (a)
anti-Thy-l and (b) anti-Lyt-2. The fine line ( ) represents
autofluorescence. In (a) the positive populations are considered
to begin at 1.7 units on the arbitrary fluorescence intensity
(logl0) scale. The Thy-l antigen is shed in culture and non
specifically binds to B-cells causing them to stain slightly more
brightly than autofluorescence.
week of tumour growth except in 2 out of 5 mice that were
injected with Ly-6.2- cells. In the thymuses of these mice
there were small reductions in the Thy-l bright and Lyt-2+
populations and a small increase in the Ly-6.2+ cells
suggesting an intermediate stage in the progression towards
the medullary thymocyte profile (Figure 4).
By this route of tumour injection, however, the spleens
from both groups of mice injected with Ly-6.2+ and Ly-6.2-
tumour cells were greatly enlarged (see Table I). There were
fewer cells in the size range of lymphocytes. Both T-cell and
B-cell numbers were markedly reduced and all remaining T-
cells were Lyt-2 positive. A scatter diagram on the basis of
cell size is shown in Figure 6a. Apart from cells in the size
range of lymphocytes (B) there were two other populations
of larger cells in the spleens of mice injected with the Ly-
6.2+ tumour cells. One of these large cell populations was
intermediate in size (C) between the lymphocytes and the
population of largest cells (D). The anti-Ly-6.2 staining
profiles of the intermediate (C) and the largest cells (D) are
shown in Figure 6b. Population (D) was clearly Ly-6.2+ and
as brightly staining as the tumour cells obtained from the
tumour mass (Figure 6c). This population thus represented
invading tumour cells. Cells in population (C) were only
marginally brighter than the background and were also Thy-
1-, Lyt-l - and Lyt-2-; they were probably of the
monocyte-macrophage series. Even though the spleens of
mice injected with Ly-62- EL4 tumour cells were enlarged
during the- second and third weeks of tumour growth, FACS
analysis revealed only one population of large cells
corresponding to population (C) which were not Ly-6.2+
and not tumour cells by size or staining criteria (Figure 6d)
even though by the third week at least 50% of tumour cells
recovered from the solid intramuscular mass were Ly-6.2+
(Figure 5).
In all mice injected with the Ly-6.2 positive subline of EL4
the tumour cells also metastasised to the mesenteric lymph
nodes. All the cells in the size range of tumour cells were Ly-
6.2+ as were the tumour cells from the intramuscular mass
(Figure 7). Only in 2 mice out of 6 injected with the Ly-6.2-
subline were the mesenteric lymph nodes invaded. The cells
in the size range of tumour cells in these lymph nodes were
both Ly-6.2- and Ly-6.2+ as were the tumour cells from the
intramuscular mass (Figure 8).
Discussion
In this study we have demonstrated that Ly-6.2 antigen
expression on EL4 tumour cells gradually declines in culture
but the antigen is re-expressed by in vivo passage in syngeneic
hosts (Figure 1). An Ly-6.2- subline separated by FACS
analysis maintained this phenotype over a long period of in
vitro passages while an Ly-6.2+ subline gradually became
heterogeneous in expression of this determinant with a
proportion of cells becoming Ly-6.2-. The Ly-6.2- and
Ly6.2+ tumour sublines had identical growth patterns in
vitro, produced similar sized growths when injected sub-
cutaneously or i.m. but mice injected with Ly-6.2- tumour
cells survived a week longer than those injected with the
same number of Ly-6.2+ cells. The latter died in three
weeks.
There were no changes in lymphocyte profiles after one
week of tumour growth in either the Ly-6.2- or the Ly-6.2+
tumour bearing groups of mice. A positive immune response
to EL4 by C57BL/6 mice one week after tumour challenge
has been reported (Apffel et al., 1966; Kemp et al., 1973)
which is consistent with an uncompromised lymphoid
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Figure 4 FACS analysis of thymocytes from normal ( ) and tumour bearing mice ( and - ) stained with (a)
anti-Thy-1, (b) anti-Lyt-2 and (c) anti-Ly-6.2. The dotted (. ) line in (a) represents autofluorescence. In (c) fluorescence of
cells with second step alone has been omitted since it very closely coincides with the normal staining profile, there being only 1%
Ly-6.2+ cells in the thymus of normal C57BL/6 mice. The altered profiles ( ) in the tumour bearing mice indicate selection of
the mature medullary thymocytes. The dashed lines ( ----- ) represent an intermediate stage in this selection process.
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Figure 5 FACS analysis of EL4 tumour cells recovered from
the peritoneal cavities of C57BL/6 mice injected with (a) Ly-6.2-
and (b) Ly-6.2+ tumour cells. The thick line ( ) represents
staining of tumour cells with anti-Ly-6.2 and the thin line ( )
staining with second step alone.
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Figure 8 Ly-6.2 staining ( ) of large cells in the size range
of tumour cells from (a) mesenteric lymph nodes and (b)
intramuscular tumour mass of C57BL/6 mice injected i.m. with
Ly-6.2- EL4 tumour cells. The fine line ( ) represents
staining with second step alone.
system. After the second week of tumour growth, when the
immune response is known to be impaired, there were
marked alterations in lymphocyte profiles. These were
identical for both Ly-6.2+ and Ly-6.2- tumour bearing mice
and involved regression of the thymus with the residual cells
expressing the phenotypes of mature medullary cells (Figure
4) as described for C57BL/6 mice after a single i.p. injection
of 125mgkg-t hydrocortisone acetate (Micklem et al.,
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lymphoid organs with the remaining T-cells being almost
totally of the Lyt-2+ subset (Figure 3) (Matossian-Rogers &
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Figure 6 (a) Scatter diagram of spleen cells from 4
injected i.m. with Ly-6.2+ EL4 tumour cells. The
populations of cells are (A) dead cells, (B) lymphoc
of intermediate size between lymphocytes and tum
tumour cells; (b) Ly-6.2 staining profiles of cell pc
(------ ) and (D) ( ). The fine line (
staining of cells with second step alone; (c) Li
and second step alone ( ) of EL4
derived from the intramuscular mass from C57BL/6
with Ly-6.2+ tumour cells; (d) Ly-6.2 staining (-
second step alone ( ) of large spleen cells (I
from C57BL/6 mice injected i.m. with Ly-6.2- EL4
Tumour cells (population D) were absent in the sp
mice.
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Figure 7 Ly-6.2 staining ( ) of large cells in
of tumour cells from (a) mesenteric lymph n(
intramuscular tumour mass of C57BL/6 mice inje(
Ly-6.2+ EL4 tumour cells. The fine line (
staining with second step alone.
We have shown that Lyt-2+ cells are selectively resistant
to corticosteroid treatment, both in peripheral lymphoid
organs (Rogers & Matossian-Rogers, 1982) and also within
the putative mature thymocyte population (Rogers &
Matossian-Rogers, 1981). Thus selective lymphocytolysis
with a resultant predominance of the Lyt-2+ subset is a
characteristic of both tumour bearing and corticosteroid
treated mice and suggests a common mechanism for the
immunnsunnressed state in these two conditions. Several 2 3 4 a L&F F %I J J v%g *s '"_a L%'_ -vL %' L
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other strains of mice injected with syngeneic tumours such as
BALB/c with Meth.A, DBA/2 with P815, C3H with Gardner
C57BL/6 mice and C57BL/6 with Gil4, showed the same effects of thymus
4 discernible regression and lymphocytolysis. Cell free extracts of tumour
.ytes, (C) cells cells obtained by freeze-thawing or sonication did not cause
iour cells, (D) similar effects (unpublished data).
)pulations (C) In spite of identical changes produced in the immune
-) represents system, the Ly-6.2- and Ly-6.2+ tumour subsets differed in
y-6.2 staining their metastatic capacity. Both subsets injected i.m. caused
tumour cells spleen enlargement during the second week of tumour
- -
i
) and growth, but tumour cells were detected only in the group
opulation C) injected with Ly-6.2+ tumour cells (Figure 6a,b). The large
tumour cells. bulk of cells causing spleen enlargement in both groups of
leens of these mice were of a size intermediate between lymphocytes and
tumour cells and were negative for both T- and B-cell
markers. Similar cells, probably belonging to the monocyte-
macrophage series were noted in C3H mice carrying the
syngeneic Gardner tumour. These cells were strongly
cytostatic against the Gardner tumour in in vitro assays
when suppressor T-cells were removed from the cell
population (Matossian-Rogers & Taidi, 1983). Spleen
enlargement is thus a host response to tumour growth and
not necessarily indicative ofmetastatic spread to this organ. The mechanism by which Ly-6.2 expression aids metastasis
is not clear. Ly-6.2 is a lymphocyte differentiation antigen
present on mature medullary thymocytes, 5-10% of bone
3 4 marrow cells, 50 60% of B and 70% of T-lymphocytes. The
expression on T-cells increases approximately 6-fold on
activation (Matossian-Rogers et al., 1982). Thus the increase
odes and (b) in Ly-6.2 must have a physiological role in the function of
cted i.m. with activated lymphocytes. It is possible that it plays a role in
-) represents enhancing migratory capacity both in normal and leukaemic
cells. The Ly-6.2- tumour cells did not appear to be totally
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devoid of migratory potential. In 2 out of 6 mice injected
with Ly-6.2- tumour cells the mesenteric lymph nodes were
invaded but cells in the size range of the tumour cells were
both Ly-6.2+ and Ly-6.2-. Since the tumour cells from the
intramuscular mass also contained Ly-6.2+ and Ly-6.2- cells
(Figure 8), the latter may have gained access to the
mesenteric lymph nodes as passengers transported by the Ly-
6.2+ cells. Ly-6.2- tumour cells, however, were never
observed in the spleens of mice injected i.p. or i.m. This may
be due to the accumulation of cytostatic cells in the spleen or
locally at sites of tumour growth or other mechanisms
creating a stronger barrier to metastasis which could only be
overcome by the greater metastatic capacity of the Ly-6.2+
tumour cells. Mice injected with Ly-6.2+ tumour cells died a
week earlier than those injected with Ly-6.2- cells. Since the
two subsets had identical growth rates in vitro and produced
similar sized growths when injected s.c. or i.m. it is assumed
that the earlier death of the mice injected with Ly-6.2+ cells
was due to the metastatic spread.
Our results are in disagreement with those of Altevogt et
al. (1982) which demonstrates a number of differences in cell
surface glycoproteins between a murine T-lymphoma line Eb
and its metastatic variant ESb. These differences include loss
of Thy-1, Lyt-2,3 as well as Ly-6 by the metastatic variant.
Such widespread differences in cell phenotype suggest the
unrelatedness of the parental and the metastatic variant cell
lines. The occasional development of ESb variants from
cloned Eb tumour cell populations was noted by these
workers in tumours passaged in ascites and taken as
evidence for the original identity of the two cell lines.
Metastatic variants derived in vivo may be due to fusion
with normal host cells (De Baetselier et al., 1984) intro-
ducing surface determinants of different cell lineages to the
tumour variant and consequently different organ colonising
potential. The in vivo increase of Ly-6.2 in our experiments
directly correlates with metastatic potential and both charac-
teristics are lost by in vitro culture of the tumour cell
population. Other surface determinants such as Thy-l and
T30 were not altered by in vivo or in vitro culture.
The mechanism for gain or loss of Ly-6.2 is not known at
present but cannot be explained by random phenotypic drift
which occurs during the proliferation of single cell clones
(Poste et al., 1981, 1982). In the present experiments the
stringent criteria for separation of Ly-6.2- and Ly-6.2+ cells
resulted in pure subpopulations, the former of which
retained its phenotypic characteristics in vitro and the latter
in vivo. It is well known that polyclonal but uniform
populations of tumour cells are more phenotypically stable
and less susceptible to diversification than populations
derived from single cell clones (Miner et al., 1982). The
increased expression of Ly-6.2 is thus a specific event during
the metastatic cascade and is applicable to the tumour
population as a whole. The mechanism for this increase may
be enhancement or induction of mRNA analogous to the
proposed mechanism for interferon induced modulation of
major histocompatibility complex (MHC) gene products
(Rosa et al., 1985) or other mechanisms leading to activation
or expression of genes such as hypomethylation of DNA
(Frost et al., 1984). Gradual hypomethylation due to local in
vivo environmental conditions may result in the expression of
genes which are involved in tumour progression and
increased metastatic aggressiveness. The rate of conversion
of Ly-6.2- tumour cells to the Ly-6.2+ phenotype suggests
that the mechanisms in operation must be under the
influence of inductive rather than selective processes. Thus
certain host or tumour induced signals or host-tumour cell
interactions initiate the gene activation or amplification
mechanisms or the transcriptional and translational controls
that may be involved in the process of antigen expression.
It is now generally accepted that metastatic capacity of
tumour cells correlates with phenotypic variation (Albino et
al., 1981; Natali et al., 1983; Stackpole, 1983) rather than
ultrastructural differences between metastatic and non-
metastatic variants (Franks & Layton, 1984). Experimental
induction of MHC molecules in some tumour cell lines
lacking in these determinants has demonstrated the
involvement of immune phenomena in modulating metastatic
spread (Hui et al., 1984; Wallich et al., 1985). Other cell
surface molecular differences between metastatic and non-
metastatic tumour variants are thought to affect cell-cell and
cell-tissue interactions influencing adhesiveness and organ
colonising properties of tumour cells (Reiber & Reiber, 1981;
Sargent et al., 1983). Non-specific defence mechanisms have
also been shown to control tumour cell dissemination
(Barlozzari et al., 1985).
In view of the multiplicity of mechanisms operating in the
inhibition of metastatic spread of tumours a number of
model systems must be examined to understand the
phenomenon of metastasis more fully. In the model system
presented in this report the cell surface modifications
affecting metastasis occur naturally in-vivo and dissemination
is spontaneous from a primary site. This is clinically more
relevant than models of metastasis where the tumour cells
are introduced directly into the blood stream by i.v.
inoculation (Sinha & Goldenberg, 1974; Tarin & Price, 1979;
Reiber & Reiber, 1981) since organ colonisation by this
method does not necessarily indicate the potential for spon-
taneous dissemination from a locally growing tumour
(Stackpole, 1981). Further study of this model may shed
light upon the normal physiological role of Ly-6.2 on
lymphoid cells and the intrinsic capacity of tumour cells to
initiate their metastatic spread.
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